Linagliptin API Manufacturers

compare suppliers & get competitive offers

Filters

Reset

Selected filters:

Type
Production region
Qualifications
Country of origin

TOP RANKING

Located in:

Poland

Producer

Produced in:

Poland

Established in: 1951

MOQ: -

Employees: 455+

Largest Polish manufacturer of pharmaceuticals and a leader of the Polish pharmaceutical market.

FDA approved european manufcaturing facilities

Export APIs to more than 60 countries worldwide

  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • FDA

  • DMF

  • KDMF

  • GMP

  • CoA

  • EDMF/ASMF

  • MSDS

  • BSE/TSE

Contact supplier

Replies quickly

TOP RANKING

Located in:

India

Produced in:

India

Established in: 1984

MOQ: -

Employees: 2000+

Vertically integrated company

Largest producer of Montelukast in the world

USFDA & WHO GMP approved API plants

  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • DMF

  • WC

  • GMP

  • CoA

  • EDMF/ASMF

  • FDA

  • ISO9001

  • MSDS

  • BSE/TSE

Contact supplier

Replies quickly

HIGHLIGHTED

Located in:

India

Produced in:

China

MOQ: 1 kg

  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • CoA

  • BSE/TSE

  • DMF

  • ISO9001

  • WHO-GMP

  • GMP

Contact supplier

Replies quickly

HIGHLIGHTED

Located in:

Turkey

Producer

Produced in:

Turkey

Established in: 2022

MOQ: -

Employees: 100+

Operating on GMP guidelines with the most recent technologies and equipment

High-quality products at unrivaled prices

Specialize in Narcotic and Non-Narcotic APIs

  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • DMF

  • WC

  • GMP

  • CoA

  • MSDS

Contact supplier

Replies quickly

HIGHLIGHTED

Located in:

United States

Produced in:

United States

Established in: 1994

MOQ: -

Employees: 50+

26+ years of distribution expertise with regulatory excellence

16 worldwide locations supplying high quality ingredients

All our manufacturer partners are cGMP complaint

  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • GMP

  • CoA

  • ISO9001

  • MSDS

  • BSE/TSE

Contact supplier

Replies quickly

Located in:

China

Produced in:

China

Established in: 1987

MOQ: -

Passed ISO9001:2015 and SGS audit

Provide one-stop CDMO service from R&D to production

Certifications: ISO9001: 2015, HALAL Certificate, Kosher Certification

  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • DMF

  • GMP

  • CoA

  • ISO9001

  • MSDS

Contact supplier

Replies quickly

Produced in:

China

Established in: 2011

MOQ: 100 g

Employees: 10+

Fast Response and Good Communication

Willingness To Start From Small

Flexible Payment Terms

  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • CoA

  • BSE/TSE

  • MSDS

  • WC

  • DMF

  • ISO9001

Contact supplier

Replies quickly

Located in:

China

Produced in:

China

MOQ: -

  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • DMF

  • CoA

Contact supplier

Replies slower than most

Located in:

Germany

Producer

Produced in:

Unknown

MOQ: -

  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • DMF

  • CoA

Contact supplier

Replies slower than most

Located in:

Italy

Producer

Produced in:

Italy

MOQ: -

  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • GMP

  • CoA

Contact supplier

Replies slower than most

Located in:

China

Produced in:

China

MOQ: -

  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • DMF

  • CoA

Contact supplier

Replies slower than most

Located in:

China

Produced in:

China

MOQ: -

  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • DMF

  • CoA

Contact supplier

Replies slower than most

Located in:

India

Producer

Produced in:

India

MOQ: -

  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • DMF

  • WC

  • CoA

  • GMP

Contact supplier

Replies slower than most

Located in:

China

Produced in:

China

MOQ: -

  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • coa

Contact supplier

Replies slower than most

Located in:

China

Produced in:

China

MOQ: -

  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • DMF

  • CoA

Contact supplier

Replies slower than most

Producer

Produced in:

Unknown

Established in: 1944

MOQ: -

Employees: 4,000

14 international API plant sites

Portfolio of 350+ APIs

Teva is among the world’s largest generic drug/API manufacturers

  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • DMF

  • CoA

Contact supplier

Replies quickly

Located in:

Germany

Produced in:

Germany

MOQ: -

  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • GMP

  • CoA

Located in:

India

Producer

Produced in:

India

MOQ: -

  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • DMF

  • CoA

Located in:

India

Producer

Produced in:

India

MOQ: -

  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • GMP

  • WC

  • CoA

  • DMF

Located in:

China

Produced in:

China

MOQ: -

  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • coa

Located in:

India

Producer

Produced in:

India

MOQ: -

  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • DMF

  • GMP

  • WC

  • CoA

How does it work?

1
Register for free
icon

You can register for free as long as you are registering on behalf of a legal company related to the pharmaceutical industry

2
Start sourcing
icon

Search in the search bar the product that you’re looking for. We’ll show you an overview of all available suppliers. Use the filters to select the relevant suppliers only

3
Send inquiries
icon

Have you found interesting suppliers? Then it’s time to contact them. Use the send inquiry button and send them a message. You can send for each product, 3 inquiries per week

4
Get quotation
icon

Suppliers get notified by Pharmaoffer that they’ve received a new inquiry. They will come back to you with their questions, certificates, and offer in the chat on Pharmaoffer. We will send you an email in case of any news

5
Arrange agreement
icon

Does the supplier meet your quality and commercial requirements? Then you can place the order. Just follow the steps of our order module

Looking for Linagliptin API 668270-12-0?

Description:
Here you will find a list of producers, manufacturers and distributors of Linagliptin. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
API | Excipient name:
Linagliptin 
Synonyms:
Tradjenta , Trajenta , Linagliptin Form C  
Cas Number:
668270-12-0 
DrugBank number:
DB08882 
Unique Ingredient Identifier:
3X29ZEJ4R2

About Linagliptin

Here, you can find what Linagliptin is used for, in short. Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes. Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin was approved by the FDA on May 2, 20115.

You can ask the supplier about all relevant certificates for the product such as CoA, Safety Data Sheet and DMF.

Linagliptin is a type of DPP4-Inhibitors


DPP4-Inhibitors, or dipeptidyl peptidase-4 inhibitors, belong to the subcategory of pharmaceutical active ingredients known for their therapeutic role in managing type 2 diabetes mellitus. These inhibitors work by targeting and inhibiting the action of the enzyme dipeptidyl peptidase-4 (DPP4) in the body.

DPP4 is responsible for breaking down incretin hormones, such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). By inhibiting DPP4, DPP4-Inhibitors enhance the levels and activity of these hormones. GLP-1 and GIP play crucial roles in regulating blood sugar levels by stimulating insulin release, inhibiting glucagon secretion, and slowing down gastric emptying.

The main advantage of DPP4-Inhibitors is their ability to improve glycemic control without the risk of hypoglycemia, which is a common side effect of some other diabetes medications. They are typically used as an adjunct therapy in combination with other antidiabetic agents, such as metformin, to achieve optimal glucose management.

Commonly prescribed DPP4-Inhibitors include sitagliptin, saxagliptin, linagliptin, and alogliptin. These drugs are available in oral tablet formulations, allowing for convenient administration. They have shown efficacy in lowering HbA1c levels and have a favorable safety profile.

It is important to note that DPP4-Inhibitors are not suitable for individuals with type 1 diabetes or those with a history of pancreatitis. As with any medication, there may be potential side effects, such as upper respiratory tract infections, headache, and gastrointestinal discomfort, which should be discussed with a healthcare professional.

In conclusion, DPP4-Inhibitors are a subcategory of pharmaceutical APIs that act by inhibiting the enzyme DPP4, thereby enhancing the effects of incretin hormones involved in glucose regulation. They are widely used in the management of type 2 diabetes mellitus, offering glycemic control benefits with a reduced risk of hypoglycemia.


Linagliptin (DPP4-Inhibitors), classified under Anti-diabetics


Anti-diabetics, belonging to the pharmaceutical API (Active Pharmaceutical Ingredient) category, are a group of compounds designed to manage and treat diabetes mellitus, a chronic metabolic disorder characterized by high blood sugar levels. These medications play a vital role in controlling diabetes and preventing complications associated with the disease.

Anti-diabetics encompass a wide range of drug classes, including biguanides, sulfonylureas, thiazolidinediones, dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose cotransporter-2 (SGLT2) inhibitors, and glucagon-like peptide-1 (GLP-1) receptor agonists. Each class works through different mechanisms to regulate blood sugar levels and improve insulin sensitivity.

Biguanides, such as metformin, reduce glucose production by the liver and enhance insulin sensitivity in peripheral tissues. Sulfonylureas, like glipizide, stimulate insulin secretion from pancreatic beta cells. Thiazolidinediones, including pioglitazone, improve insulin sensitivity in muscle and adipose tissues. DPP-4 inhibitors, such as sitagliptin, increase insulin release and inhibit glucagon secretion. SGLT2 inhibitors, like dapagliflozin, decrease renal glucose reabsorption, leading to increased urinary glucose excretion. GLP-1 receptor agonists, such as exenatide, enhance insulin secretion, suppress glucagon release, slow gastric emptying, and promote satiety.

These anti-diabetic APIs serve as the foundational ingredients for the formulation of various oral tablets, capsules, and injectable medications used in the treatment of diabetes. By targeting different aspects of glucose regulation, they help patients achieve and maintain optimal blood sugar levels, thus reducing the risk of diabetic complications, such as cardiovascular disease, neuropathy, and nephropathy.

It is crucial for healthcare professionals to prescribe and administer these anti-diabetic medications appropriately, considering factors like the patient's medical history, co-existing conditions, and potential drug interactions. Regular monitoring of blood glucose levels and close medical supervision are necessary to ensure effective diabetes management.

In conclusion, anti-diabetics form a critical category of pharmaceutical APIs used for the treatment of diabetes. These compounds, encompassing various drug classes, work through distinct mechanisms to regulate blood sugar levels and improve insulin sensitivity. By facilitating glucose control, anti-diabetic APIs help mitigate the risk of complications associated with diabetes mellitus, ultimately promoting better health outcomes for patients.



Linagliptin manufacturers | traders | suppliers

We have 21 companies offering Linagliptin produced in 8 different countries.

Get in contact with the supplier of your choice:

  • Polpharma from Poland, product country of origin Poland
  • Morepen Laboratories Ltd. from India, product country of origin India
  • Solfyn International LLP from India, product country of origin China
  • PluviaEndo from Turkey, product country of origin Turkey
  • Rochem International, Inc. from United States, product country of origin United States
  • Sinoway industrial Co.,Ltd from China, product country of origin China
  • Shandong Octagon Chemicals Limited from China, product country of origin China
  • Fuxing Long Rui Pharma from China, product country of origin China
  • HEC Pharm from Germany, product country of origin Unknown
  • Bidachem from Italy, product country of origin Italy
  • Wisdom Pharma from China, product country of origin China
  • Beijing Huikang Boyuan from China, product country of origin China
  • Honour Lab from India, product country of origin India
  • Chengdu Firster Pharmaceutical Co Ltd from China, product country of origin China
  • Shanghai Wonder Pharma from China, product country of origin China
  • Teva API from Israel, product country of origin Unknown
  • Boehringer Ingelheim from Germany, product country of origin Germany
  • Sun Pharma from India, product country of origin India
  • MSN Pharma from India, product country of origin India
  • Shaoxing Hantai Pharma from China, product country of origin China
  • Mylan from India, product country of origin India

Let the supplier know whether you are looking for a product with a specific monograph such as EP (Ph. Eur.), USP, JP, BP or another quality. Or, whether you are looking for hydrochloride (HCl), anhydricum, base, micronisatum or a specific purity.

You can use the filters to find high-quality suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our FAQ page or use the chat box in the corner to get more information about Pharmaoffer.